Verastem, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Daniel W. Paterson
- Full Time Employees
- 102
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 117 Kendrick Street Needham MA United States of America 02494
- IPO Date
- Jan 27, 2012
- CIK
- 0001526119
- Website
- verastem.com
- Similar Companies
- Business
- Verastem, Inc. Verastem, Inc. (VSTM) is a late-stage biopharmaceutical company focused on developing and commercializing novel small molecule drugs targeting the RAS/MAPK signaling pathway in cancer, including RAF/MEK inhibition via avutometinib, FAK inhibition via defactinib, and KRAS G12D inhibition via VS-7375; the company advances these assets in monotherapy and combinations for low-grade serous ovarian cancer (LGSOC), pancreatic cancer, non-small cell lung cancer, colorectal cancer, and other RAS/MAPK-driven solid tumors, supported by investigator-sponsored trials and combinations with agents such as paclitaxel, pegylated liposomal doxorubicin, letrozole, anastrozole, and cetuximab. Founded in 2010 and headquartered in Needham, Massachusetts, Verastem operates primarily in the United States with a global development strategy through partnerships, employing approximately 78 people under CEO Daniel Paterson. In recent developments, the U.S. FDA approved the avutometinib plus defactinib combination (AVMAPKI FAKZYNJA) as the first therapy for adult patients with KRAS-mutant recurrent LGSOC, with commercialization underway following a planned mid-2025 launch; the company refinanced debt with Oberland Capital, entered a strategic commercialization partnership with IQVIA, completed a $75 million private placement, advanced the GenFleet Therapeutics collaboration with Phase 1/2 initiation of VS-7375 (GFH375) in July 2024 after Chinese IND approval in June 2024, and outlined 2025 priorities including RAMP trials and pipeline expansion.
Company News
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
Head to Head Survey: Verastem (NASDAQ:VSTM) & Sangamo Therapeutics (NASDAQ:SGMO)
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
Verastem (NASDAQ:VSTM) Shares Up 7.1% – Time to Buy?
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright
Verastem, Inc. (NASDAQ:VSTM) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Bank of New York Mellon Corp Makes New Investment in Verastem, Inc. $VSTM
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
Verastem Oncology to Participate in Upcoming September Investor Conferences
Verastem: A Rare-Disease Launch Is Financing A KRAS G12D Platform
Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of “Moderate Buy” from Analysts
Verastem Q2 Earnings Call Highlights
Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript
Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer